Skip to main content

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Publication ,  Journal Article
Flaig, TW; Spiess, PE; Agarwal, N; Bangs, R; Boorjian, SA; Buyyounouski, MK; Downs, TM; Efstathiou, JA; Friedlander, T; Greenberg, RE; Guru, KA ...
Published in: J Natl Compr Canc Netw
September 2018

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

September 2018

Volume

16

Issue

9

Start / End Page

1041 / 1053

Location

United States

Related Subject Headings

  • Urinary Bladder Neoplasms
  • United States
  • Treatment Outcome
  • Societies, Medical
  • Randomized Controlled Trials as Topic
  • Radiotherapy, Adjuvant
  • Quality of Life
  • Patient Selection
  • Organ Sparing Treatments
  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Flaig, T. W., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., … Gurski, L. A. (2018). NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw, 16(9), 1041–1053. https://doi.org/10.6004/jnccn.2018.0072
Flaig, Thomas W., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Tracy M. Downs, et al. “NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.J Natl Compr Canc Netw 16, no. 9 (September 2018): 1041–53. https://doi.org/10.6004/jnccn.2018.0072.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 Sep;16(9):1041–53.
Flaig, Thomas W., et al. “NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.J Natl Compr Canc Netw, vol. 16, no. 9, Sept. 2018, pp. 1041–53. Pubmed, doi:10.6004/jnccn.2018.0072.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 Sep;16(9):1041–1053.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

September 2018

Volume

16

Issue

9

Start / End Page

1041 / 1053

Location

United States

Related Subject Headings

  • Urinary Bladder Neoplasms
  • United States
  • Treatment Outcome
  • Societies, Medical
  • Randomized Controlled Trials as Topic
  • Radiotherapy, Adjuvant
  • Quality of Life
  • Patient Selection
  • Organ Sparing Treatments
  • Oncology & Carcinogenesis